UCB0599 | UCB
UCB's Global Corporate Website

UCB0599

Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available)
Parkinson's Disease (PD) A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease Phase 2 PD0053
Ongoing
NCT04658186
2020-003265-19
Parkinson's Disease (PD) An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of UCB0599 in Study Participants With Parkinson's Disease Phase 2 PD0055
Ongoing
NCT05543252